DUBLIN, Sept. 14, 2018 /PRNewswire/ --
The "Monoclonal Antibodies Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
The monoclonal antibodies market is projected to grow at a CAGR of 6.34% to reach US$131.766 billion by 2023, from US$91.122 billion in 2017.
The market for monoclonal antibodies is driven by persistent innovation in drug development and discovery, increasing incidences of chronic diseases, favorable regulatory policies, and high adoption rate of therapeutic antibodies in emerging economies.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments.
Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions.
Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Key Topics Covered
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Product Pipeline
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. MONOCLONAL ANTIBODIES MARKET BY INDICATION
5.1. Inflammatory Disease
5.3. Microbial Disease
6. MONOCLONAL ANTIBODIES MARKET BY SOURCE
7. MONOCLONAL ANTIBODIES MARKET BY APPLICATION
8. MONOCLONAL ANTIBODIES MARKET BY END-USER
8.1. Hospitals & Clinics
8.2. Research Laboratories
9. MONOCLONAL ANTIBODIES MARKET BY GEOGRAPHY
9.1. North America
9.2. South America
9.4. Middle East and Africa
9.5. Asia Pacific
10. COMPETITIVE INTELLIGENCE
10.1. Market Share Analysis
10.2. Recent Investment and Deals
10.3. Strategies of Key Players
11. COMPANY PROFILES
11.1. Eli Lilly and Company
11.2. AbbVie, Inc.
11.3. Novartis AG
11.4. Bristol Myers Squibb
11.5. F. Hoffmann-La Roche Ltd.
11.6. Johnson & Johnson Services, Inc.
11.7. Amgen Inc.
11.8. Merck & Co. Inc.
11.10. AstraZeneca PLC
For more information about this report visit https://www.researchandmarkets.com/research/528s58/global_monoclonal?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets